in the absence of a submission from the holder of the marketing authorisation
pegcetacoplan (Aspaveli®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.
This advice refers to use in treatment naive patients. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result, we cannot recommend its use within NHSScotland.
SMC has previously accepted pegcetacoplan (Aspaveli) for restricted use for treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months (SMC2451). This advice remains valid.
Download detailed advice237KB (PDF)
Medicine details
- Medicine name:
- pegcetacoplan (Aspaveli)
- SMC ID:
- SMC2715
- Indication:
As monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.
- Pharmaceutical company
- Swedish Orphan Biovitrum
- BNF chapter
- Nutrition and blood
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 September 2024